

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report: May 30, 2013
(Date of earliest event reported)

BIORESTORATIVE THERAPIES, INC.
(Exact Name of Registrant as Specified in Charter)

Nevada	000-54402	91-1835664
(State or Other Jurisdiction of Incorporation)	(Commission File No.)	(IRS Employer Identification Number)
<u>555 Heritage Drive, Jupiter, Florida</u>		<u>33458</u>
(Address of Principal Executive Offices)		(Zip Code)

Registrant's telephone number, including area code: (561) 904-6070

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01 Regulation FD Disclosure.

BioRestorative Therapies, Inc. (the “Company”) has prepared presentation materials (the “Presentation Materials”) that management intends to use from time to time on and after May 30, 2013 in presentations about the Company’s business. The Company intends to use the Presentation Materials, possibly with modification, at the Marcum Microcap Conference being held on May 30, 2013 and may use the Presentation Materials in other presentations to current and potential investors, lenders, creditors, insurers, vendors, customers, employees and others with an interest in the Company and its business.

The information contained in the Presentation Materials is summary information that should be considered in the context of the Company’s filings with the Securities and Exchange Commission and other public announcements that the Company may make by press release or otherwise from time to time. The Presentation Materials speak as of the date of this Current Report on Form 8-K. While the Company may elect to update the Presentation Materials in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, the Company specifically disclaims any obligation to do so. The Presentation Materials are furnished as Exhibit 99.1 to this Current Report on Form 8-K and are incorporated herein by reference. The presentation materials will also be posted in the Investor Relations section of the Company’s website, www.biorestorative.com for 90 days.

The information referenced under Item 7.01 (including Exhibit 99.1 referenced in Item 9.01 below) of this Current Report on Form 8-K is being “furnished” under “Item 7.01. Regulation FD Disclosure” and, as such, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information set forth in this Current Report on Form 8-K (including Exhibit 99.1 referenced in Item 9.01 below) shall not be incorporated by reference into any registration statement, report or other document filed by the Company pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Presentation Materials.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIORESTORATIVE THERAPIES, INC.

Dated: May 30, 2013

By: /s/ Mark Weinreb

Mark Weinreb

Chief Executive Officer

BIORESTORATIVE THERAPIES, INC.

Mark Weinreb, CEO

OTCBB: BRTX

biorestorative.com

May 2013

Forward Looking Statements

This presentation contains "forward-looking statements" within the meaning of the federal securities laws, including statements concerning the ability of BioRestorative Therapies, Inc. (the "Company") to develop its adult stem cell business, the future of regenerative medicine and the role of adult stem cells in that future, and the potential revenue growth of the Company's business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: (1) the Company's limited operating history, lack of significant revenues, substantial losses since inception, and substantial working capital deficiency and stockholders' deficiency, (2) the Company's ability to obtain sufficient financing to satisfy its debt obligations and funds its operations, (3) the ability of the Company to obtain reimbursement for its therapies from private and governmental insurers, (4) the Company's ability to build management, human resources and infrastructure necessary to support the growth of its business, (5) competitive factors beyond the Company's control, (6) scientific and medical developments beyond the Company's control, (7) the Company's ability to comply with applicable federal, state, local, and international governmental requirements, (8) the Company's ability to protect its proprietary rights both within and outside the United States, and (9) other factors discussed in the Company's periodic documents filed with the Securities and Exchange Commission (which are available for review at www.sec.gov). Given these uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. We assume no obligation to update these forward-looking statements to reflect actual results or changes in factors or assumptions affecting such forward-looking statements.

Investment Highlights


- **BioRestorative Therapies (“BRT”)** is a biotechnology company that develops medical procedures using cell and tissue protocols, primarily involving adult stem cells, designed for patients to undergo minimally invasive cellular-based treatments
- **Focused on 3 Programs:**
 - Bulging/Herniated Discs – *brtxDISC™ Program*
 - Metabolic Diseases/Obesity - *ThermoStem® Program*
 - Cosmetic Extract – *brtx-C Cosmetic Program*
- **Potential for Significant Near-Term Value Creation**
 - Spinal disc program is potentially poised to enter Phase II (retrospective human safety/feasibility being studied)
 - Cosmetic program is commercial-ready for incorporation into third party beauty care products

brtxDISC™ Overview



- **brtxDISC™ (Disc Implanted Stem Cells) Program**
 - Non-surgical cellular, regenerative therapy for treatment and relief of bulging and herniated discs
 - Utilizes autologous stem cells to repair damaged tissue, within the disc, through regenerative medicine
 - Developed IP for culturing optimal cell population for disc repair
 - Company-developed brtxDISC™ cell delivery device
 - Addresses unmet medical need between non-invasive and surgical procedures, representing a large market opportunity
 - Research in non-clinical investigative stage

TM ***brtxDISC* Target Markets**



brtx
disc^x

biorestorative
therapies




brtxDISC™ Proprietary Approach

Cell Culturing

Selects mesenchymal stem cells (MSCs) that can survive in low oxygen (hypoxic) environment.


Cell Delivery

MSC cells are injected into posterior disc annulus using the brtxDISC™ cell delivery device allowing for precise delivery to the damaged region within the disc.




brtxDISC™ Cell Delivery Device

Patent-pending Cell Delivery Device



brtxDISC™ Process Overview



brtxDISC™ Market Size & Costs

Procedure	Annual Incidence (U.S.)	Surgical Cost	brtxDISC™ (Estimated Cost)	Savings Per Patient
Spinal Fusion	300,000	\$75-100K	\$18K	\$57-82K
Disc Replacement	200,000	\$35-50K	\$18K	\$17-32K
Discectomy	200,000	\$20-50K	\$18K	\$2-32K

- Surgical procedures are typically followed by an additional \$100-150K in rehabilitation costs.
- Addressable market is estimated to be 1,000,000 patients per year in the U.S.

brtxDISC™ MRI Results

- **42 y/o Male:** Annular tear at L5-S1 noted on 2003 MRI and radiculopathy diagnosed. 2007 MRI showed a mild L5-S1 disc bulge.
- **Treated in Physician's Office :** 5 month follow-up MRI showed complete resolution of the L5-S1 disc bulge on both sagittal and axial slices with some concurrent advancement of mild DDD.




MRI Before Treatment




MRI 5 Months After Treatment

brtxDISC™ Development Path

GOAL



CONSERVATIVE PATH



ThermoStem® Overview


- **Potential allogeneic brown fat stem cell treatment for metabolic disorders, primarily targeting Type 2 diabetes & obesity**
 - **“Good Fat”** (brown adipose tissue) vs. **“Bad Fat”** (white adipose tissue)
 - Initial non-clinical research indicates that brown fat is present in the human body and may be responsible for additional caloric burning as well as reduced glucose and lipid levels in the body.
- **Potential uses may include inducing weight loss (“biologic diet”) and the reduction of glucose and lipids**
 - Potential to delay, prevent, or cure diabetes
- **BRT has identified the first stem cell population isolated from brown adipose depots in humans**
 - Early animal studies using this cell population have shown promising results in reducing and glucose, lipid levels, and weight.

Brown Fat Overview

“One of the most powerful organs in the body....Since it consumes both glucose and fatty acids, it is possible we could utilize brown fat to treat obesity and metabolic dysfunction seen in diabetes and hyperlipidemia.”

- Aaron M. Cypress, M.D., Ph.D., Joslin Diabetes Center and Harvard Medical School

- Babies do not have much white fat for insulation or body heat retention
- Instead, babies utilize brown fat cells loaded with heat generating mitochondria
- Heat is produced through thermogenesis (breakdown of fat molecules into fatty acids in brown fat cells)
 - Same process occurs in hibernating animals, which have more brown fat than humans
- Once the newborn baby starts eating more, developing layers of white fat, the brown fat largely dissipates




ThermoStem[®] Advantage

- BRT is developing a **novel cellular therapy**, using brown fat stem cells, to treat metabolic disorders and obesity – Strong IP
- BRT has access to human brown fat depots for research and clinical development
 - Collected over 100 specimens of human brown fat
- Identified first stem cell population isolated from mediastinal brown adipose depots in humans
- Fat to fat (homologous) transplant of tissues and cells – potentially faster development path
- Using biological scaffold method for cell delivery treatment
- Potential Pharma Product – allogeneic “Off the Shelf” product

ThermoStem[®] Scaffold

Brown Fat Cells Implanted in a Biological Scaffold



Cell delivery method incorporates subcutaneous implant of decellularized scaffold containing brown fat

Pre-Clinical – Glucose/Weight





Fig. 7. (A) Glucose levels of mice transplanted with BADSC/scaffolds and controls. (B) Weights of mice transplanted with BADSC/scaffolds and controls.

Pre-Clinical – Trig/Chol Levels



	Baseline	1Mth	2Mth	3Mth	4Mth
Trig – ctrl mg/dL	115 ± 16	147 ± 13	159 ± 21	165 ± 14	188 ± 16
Trig – tx mg/dL	120 ± 14	142 ± 15	131 ± 19	113 ± 11	114 ± 10
Chol – ctrl mg/dL	136 ± 16	151 ± 15	188 ± 26	224 ± 34	251 ± 22
Chol – tx mg/dL	125 ± 12	130 ± 14	136 ± 24	126 ± 19	130 ± 15

brtx-C Cosmetic Overview

- **BRT has developed an adult stem cell-derived extract for incorporation in third parties' beauty care products**

- Potential use as a primary ingredient for a new generation of “anti-aging” beauty care products
- Potent non-animal-based extract

- **Per initial *in vitro* studies, when applied to skin cells, appears to cause a significant increase in the production of collagen and fibronectin**

- These two proteins are essential for combating the aging of skin
- Additional safety and sensitivity studies to be conducted


brtx-C Extract Impact

Dermal Fibroblasts Without Extract



(-) lyophilized supernatant/Media



Dermal Fibroblasts With Extract



(+) lyophilized supernatant/Media

(based on initial *in vitro* studies)

brtx-C Collagen/Fibronectin



Stem Pearls[®], LLC

- Wholly-owned subsidiary of BRT
- Plant-derived stem cell cosmetic products
- Formulation developed from stem cells of rare-variety 18th century Swiss apple
- Products for sale at stempearls.com
- Intent to offer products directly and through distributors to retail, spa and medical locations



Our Pipeline

Programs

Preclinical

Phase I

Phase II

Phase III

Commercial
Ready

Core Programs:

brtx-C
Cosmetic

(No FDA Clinical Pathway Required)

brtxDISC™

Potential to
bypass

ThermoStem®

Non-Core Program:

Stem Pearls®

(No FDA Clinical Pathway Required)
(cosmetic products using plant stem cells)

BRT Near-Term Goals

- **2H 2013**

- Establish commercial agreements for brtx-C Cosmetic
- File IND/IDE for brtxDISC™ program
- File additional intellectual property
- Submit pre-clinical results for ThermoStem® for peer-reviewed publication
- File additional NIH grants

- **2014**

- Revenue from brtx-C Cosmetic program
- Initiate Phase II for brtxDISC™ program
- File IND for ThermoStem® program

THANK YOU

BIORESTORATIVE THERAPIES, INC.

OTCBB: BRTX

biorestorative.com